Press Releases

Medovex Corporation to Participate in the 10th Annual German Spine Society Meeting

Company and Its German Distributor, Aureus Medical GmbH, to Present DenerveX(TM) System Technology to the Surgical Society December 10-12, 2015 in Frankfurt Germany

ATLANTA, GA -- (Marketwired) -- 10/13/15 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the Company will be participating at the largest European spine meeting, the 10th Annual German Spine Meeting (DWG), scheduled to take place December 10-12, 2015 in Frankfurt Germany.

The German Spine Society ("DWG") is a one of a kind annual meeting, drawing spine care professionals from Germany and around Europe. Participants will share the latest information, innovative techniques and procedures, best practices, and new technologies in spine surgery.

As part of the Company's European pre-launch strategy, Medovex will co-host the meeting with its German distributor Aureus Medical GmbH, a premier distributor in surgical spine technologies. Together, they will be demonstrating the Company's DenerveX System technology for the first time to the medical society, supported by our European medical advisory board and key opinion leaders Dr. Ritter-Lang (Potsdam, Germany) and Dr. Marting Deeg (Stuttgart, Germany).

The Company's patented DenerveX System, currently in development and not yet commercially available, is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

Mr. Manfred Sablowski, Medovex Senior Vice President Sales & Marketing, stated, "We are excited to be participating in DWG 2015 in Germany. As the largest spine society in Europe and the third largest spine market in the world, it is clearly the place to introduce trends in new technologies, much like our DenerveX System technology.

Sablowski continued, "It's the key meeting to connect to German and European practitioners and to collaborate, hear differing perspectives, develop relationships and interact as we continue to proceed in the later stages of the development of our DenerveX technology and begin the pre-launch process. We believe the DWG meeting will prepare us well for our future international launch."

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

About DWG 2015

A one-of-a-kind meeting, where spine care professionals from Germany, Europe and around the globe will share the latest information, innovative techniques and procedures, best practices, and new technologies. The annual meeting provides a unique opportunity for you to learn and gain skills through dynamic and challenging educational programs, the ability to network and build relationships with your colleagues and leading experts in spine care.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

Medovex Corp.
Jason Assad
470-505-9905
Email Contact

Source: Medovex Corporation

Disclaimer

Medovex Corp. maintains this website as a service to the financial and internet communities. The site is intended to provide general information about the Company. It is not designed to be a source for making investment decisions. Medovex will make every reasonable effort to include accurate and current information on this website.

Except for the historical information contained herein, the information on the site may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company’s SEC filings.

Neither Medovex Corp nor any party involved in creating, producing or delivering this site shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user’s access, use, or liability to use the Company’s website, or any errors or omissions in the content of the Medovex Corp website.

Terms of Use
General

Medovex Corp. (“the Company”) has made a reasonable effort to provide accurate and current information on this website.

It is important to note that nothing on our website constitutes or should be construed as investment advice. Date and information presented is not furnished in connection with any sale, offer of sale, solicitation or an offer to buy a security.

Solicited Policy

Neither Medovex nor any of its employees accept or consider unsolicited ideas regarding marketing, technologies or product names. The goal is to avoid any potential misunderstandings when Medovex’s products or marketing strategies might appear similar to ideas submitted to the Company.

No Offer or Advice

This website does not constitute an offer to sell or a solicitation of an offer to buy any security referenced on this website. Medovex’s management never represents that a security, product or service discussed here, are suitable for any particular investor. We do not guarantee the accuracy, completeness or timeliness. We strongly advise that all individuals be aware of the risks involved in every business and stock. You can help protect yourself by being an educated investor by closely examining Company documents filed with the Securities and Exchange Commission (SEC) as well as all other documents that have been published.

Limitation of Liability – SEC Rule 606

Use of this website is at the viewer’s own risk. Its content including but not limited to: any graphics, links or other terms are provided on an “as is” basis without warranties or representations of any kind. The Company expressly disclaims any liability for any errors or omissions in the content included in this website. All changes (should and when they may occur) are effective immediately upon posting to this website.

Archived and Forward Information

Any reports filed with the SEC may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks, some of which may be outside the Company’s control and may include economic, political and market fluctuations. Medovex undertakes no obligation to update or revise publicly any forward looking statement whether as a result of new information, future events or otherwise.

The Company strongly recommends readers carefully review all other documents and periodic reports filed by the Company with the SEC.

Medovex cannot and does not guarantee or warrant that files available for downloading (if any) through this site will be free of infection by software viruses or other harmful computer code, files or programs.